Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07145697

The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Guangzhou General Hospital of Guangzhou Military Command · Academic / Other
Sex
All
Age
3 Years – 65 Years
Healthy volunteers
Not accepted

Summary

In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when consciousness is lost and when it returns. Dexmedetomidine, a widely used drug in clinical anesthetic practice, plays an important role in the anesthetic process due to its unique pharmacological properties. It hardly causes respiratory depression during the sedative and hypnotic process, which makes it occupy an important position in clinical anesthetic regimens. The emergence of stereoelectroencephalography (SEEG) technology has brought new opportunities for research on anesthesia mechanisms. Compared with traditional electroencephalographic (EEG), SEEG can directly penetrate into deep brain structures to record electrical activities, enabling precise localization of brain regions closely related to consciousness regulation. At present, although there have been some studies on the effects of dexmedetomidine on EEG activities, there are still many deficiencies. Most studies have focused on simple spectral analysis of EEG signals or observations of limited brain regions, lacking comprehensive multi-dimensional research on functional connectivity between brain regions, microstates, and complexity. Through monitoring key brain regions, the SEEG technology can obtain more targeted and accurate information, thereby providing strong support for comprehensively revealing the neural mechanisms of dexmedetomidine-induced loss of consciousness.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineEscalating concentrations until loss of responsiveness

Timeline

Start date
2025-04-10
Primary completion
2026-12-31
Completion
2027-06-30
First posted
2025-08-28
Last updated
2025-08-28

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07145697. Inclusion in this directory is not an endorsement.